JMJamileh Moghimi

Jamileh Moghimi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jamileh Moghimi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of intra-articular platelet-rich plasma injection versus placebo for clinical outcomes in patients with knee osteoarthritis; a double-blind, randomized trial

    by Hamid Reza Beiki, Raheb Ghorbani, Jamileh Moghimi

    Introduction: Osteoarthritis (OA) is a progressively debilitating condition that leads to musculoskeletal pain, particularly in the knee joint. Most clinical guidelines recommend platelet-rich plasma (PRP) for knee OA. However, the use of PRP in knee OA is increasing. Objectives: This study aimed to investigate the effects of intra-articular administration of PRP on the symptoms, lower limb function, and daily living activities in patients with knee OA. Patients and Methods: A double-blind, randomized, controlled clinical trial was conducted and 34 patients with grade 2 or 3 knee OA were enrolled. The knees of each participant were randomly allocated to receive either 3cc PRP injection (PRP knees) or needling only (control knees). Patients were evaluated by a general practitioner before, three, and six months after the intervention using the EuroQol-visual analog scales (EQ-VAS), the International Knee Documentation Committee (IKDC), the Western Ontario and McMaster Universities Arthritis Index (WOMAC), and the Tegner Activity Score (TAS). Results: The mean (±SD) age of patients with knee OA was 56.6 ± 10.2 years. Seventy-point-six percent of patients were female. 67.6% and 32.4% of patients were in stages 2 and 3 of the disease, respectively. IKDC, WOMAC, TAS, and EQ-VAS scores in knees under PRP injection and control of knees, three and six months after injection showed significant improvement. Three and six months after the intervention, IKDC, WOMAC, TAS, and EQ-VAS scores in the PRP and control knees were not significant (P > 0.05). Inter-group comparison indicated that the IKDC score significantly increased six months in comparison to three months (P = 0.048) in PRP knees, but not significant in the control knees (P = 0.133). TAS score in PRP and control knees significantly increased six months compared to three months after injection. WOMAC and EQ-VAS score in PRP and control knees was not significant at six months in comparison to three months after the intervention. Conclusion: Our findings could suggest safety and feasibility data for the intra-articular administration of PRP in patients with knee OA that may help to appraise a larger clinical trial. Findings show that PRP injection improves IKDC, WOMAC, TAS, and EQ-VAS scores, however, there was no significant difference with needling only (control knees). Trial Registration: The trial protocol was approved by the Iranian Registry of Clinical Trial (identifier: IRCT2015010112823N2; https://en.irct.ir/trial/12827, Ethics committee reference number: 93/551664) and Research Registry (Research Registry Unique Identifying Number: researchregistry9843).


  • Open Access

    Periodontitis and rheumatoid arthritis: A neglected association in developing countries

    by Nasibeh Alebooyeh, Jamileh Moghimi, Amir Hasani, Raheb Ghorbani, Golmehr Taheri

    Most patients with rheumatoid arthritis (RA), one of the most common inflammatory diseases, also suffer from periodontitis. This study investigated the effects of periodontal therapy on disease activity in RA patients. In this before-and-after clinical trial study, 30 patients with simultaneous RA and periodontitis were studied from March 2014 to February 2016. The Disease Activity Score with 28-joint Counts (DAS28) questionnaire was completed for all participants. Patients with confirmed periodontitis received non-surgical scaling, root planning, systemic antibiotics, and chlorhexidine. At days 45 and 90 after treatment, the DAS28, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were measured again. The results of the evaluation of 30 patients with a mean age of 50.2±10.62 years (80% female) showed that the difference in the level of disease activity between baseline versus 45 (5.18±0.092 vs. 4.02±1.22, P value<0.001) and 90 days later (5.18±0.092 vs. 3.84±0.92, P value<0.001), was statistically significant. Serum CRP levels (mg/dl) were lower at 90 days after treatment (5.17±2.96) than at 40 days post-treatment (5.30±3.59). The ESR values (mm/hour) at 45 (20.57±11.01) and 90 (18.23±8.99) days after periodontal therapy were lower in comparison with the baseline (21.67±11.65), but there were no significant differences between the different time points (P value˃0.05). Treating periodontitis resulted in reduced RA disease activity. Hence, routine dental examinations for faster diagnosis and treatment of periodontitis in order to relieve RA symptoms as well as further studies including a control group are recommended.

  • Open Access

    Is it the time to offer rituximab as a cost-benefit treatment for immunoglobulin A nephropathy? A short-review to current concepts

    by Mohammad-Reza Tamadon, Jamileh Moghimi, Hamed Rezaei

    Context: IgA nephropathy (IgAN) as an autoimmune disease is the most common cause of glomerulonephritis worldwide. Rituximab effectively depletes B cells and reduces serum levels of IgA1 antibodies. This paper aimed to review the potential benefit of rituximab used in clinical practice of IgAN patients. Evidence Acquisitions: PubMed, EBSCO, Web of Science, directory of open access journals (DOAJ), EMBASE, and Google Scholar were searched for the keywords of IgA nephropathy, rituximab, B cell depletion and autoimmune diseases. Results: Rituximab therapy improved in nephropathies and in recurrent IgAN in several studies. The mechanisms of rituximab therapy in IgAN are unknown. However, a direct effect of rituximab on podocytes by cytoskeleton stabilization is possible. Additionally a possible effect of rituximab on B cells in IgAN may lead to its beneficial impact. Conclusions: This short-review demonstrates that rituximab therapy may be an effective treatment option in IgAN patients, particularly for histological signs of active inflammation. However, results of safety and efficacy of rituximab in IgAN are limited, and definitive conclusions will require further studies. Thus, multicenter clinical trials for safety and efficacy of rituximab therapy are necessary.

  • Open Access

    Knowledge Towards Prevention of Osteoporosis in Adolescent Girls: Effect of Educational Program

    by Jamileh Moghimi, Zahra Safaei, Behnaz Behnam, Raheb Ghorbani

    Background: Osteoporosis is one of the most common disorders in women, affecting the quality of life by having the increasing risk of fractures. There are no data on awareness of adolescent girls as a vulnerable group about osteoporosis. Objectives: The aim of this study was to assess the knowledge concerning osteoporosis among high school female students in Semnan, Iran and to evaluate the effect of educational program. Methods: This pre and post-study was performed on 583 high-school female students, whom selected from 8 schools using multi-stage sampling. The study questionnaires were completed by interviewing students. All students participated in a single education session (about 2 hours) and the level of knowledge about osteoporosis, its risk factors and complications were assessed before and after education. Results: The mean ± SD score for general knowledge regarding osteoporosis was 0.35 ± 0.35, about complications of osteoporosis was -0.18 ± 0.53 and about risk factors for osteoporosis was also 0.25 ± 0.21. The mean total knowledge about osteoporosis was the highest in third high school grade girls (P = 0.009), while no difference was observed in score of knowledge towards osteoporosis across the different educational fields (P = 0.156). The mean total score of knowledge toward osteoporosis was significantly increased after educational intervention compared to prior to the educational program with the mean ± SD pre-educational score 0.23 ± 0.19 (median 0.26) and post-educational score 0.45 ± 0.22 (median 0.48) (P < 0.001). Conclusions: In conclusion, our results indicated that awareness of Semnan high schools girls on osteoporosis, especially about its complications is poor. Lack of awareness could be due to the lack of training. Thus, more training needed with a focus on understanding the causes of disease and its complications in order to resolve the problem and reduce the incidence of osteoporosis. So by increasing awareness regarding this disease, there is a potential for prevention and reduction of the complications. Keywords: Osteoporosis; Knowledge; Education; Prevention


    • 1 January 2016
      • Vol. 5  (2) , 41-46
    Open Access

    Retinal Toxicity in Patients Treated With Hydroxychloroquine: A Cross-Sectional Study

    by Goldis Espandar, Jamileh Moghimi, Raheb Ghorbani, Mohsen Pourazizi, Mohammad-Ali Seiri, Shervin Khosravi

    Hydroxychloroquine (HCQ) is an antimalarial medication that can also be used to treat autoimmune diseases. However, it can produce irreversible changes to the retina that lead to visual impairment. The aim of this study was to determine the proportion of patients treated with HCQ who develop retinal toxicity and the risk factors for the development of HCQ-induced retinal toxicity among Iranian patients. The is a cross-sectional clinical study of 59 patients who were treated with HCQ during 2014–2015. A questionnaire was used to collect data on the following demographic and clinical factors: age, gender, type of rheumatic disease, history of cataract surgery, daily and cumulative HCQ dose, and duration of HCQ use. Retinal toxicity was diagnosed on the basis of the automated perimetry results of the central 10° of vision and spectral domain optical coherence tomography. The associations between the demographic and clinical factors and retinal toxicity were assessed, and P < 0.05 was considered statistically significant. Retinal toxicity was detected in 18 (30.5%) of the patients, and 5 (8.5 %) developed color vision impairments. There was no association between retinal toxicity and sex (P = 0.514), history of cataract surgery (P = 0.479), type of rheumatic disease (P = 0.539), or daily HCQ dose (P = 0.062). However, there was a significant positive association between retinal toxicity and age (P = 0.006), cumulative HCQ dose (P = 0.002), and duration of HCQ use (P < 0.001). In conclusion, the risk factors for retinal toxicity after HCQ treatment were advanced age, use of a higher cumulative HCQ dose, and a longer duration of treatment.


  • Open Access

    Isotretinoin-associated Sweet’s syndrome: a case report

    by Jamileh Moghimi, Daryiush Pahlevan, Maryam Azizzadeh, Hamid Hamidi, Mohsen Pourazizi

    Sweet’s syndrome (SS) is characterized by various clinical symptoms, physical features, and pathological findings. Although cases of SS are very rare, there has been an increase in the incidence of drug-induced SS. Till date, there have been only few reported cases of isotretinoin-induced SS. In this report, we describe the case of a 19-year-old girl who developed SS after systemic treatment with oral isotretinoin for nodulocystic acne. The findings of this report emphasize the importance of evaluating isotretinoin as a possible, though uncommon, cause of SS and replacing it with another treatment if its involvement is suspected.


  • Relationship between disease activity and serum levels of vitamin D and parathyroid hormone in rheumatoid arthritis

    by J. Moghimi, A. Sadeghi, M. Malek, R. Ghorbani

    Relationship between disease activity and serum levels of vitamin D and parathyroid hormone in rheumatoid arthritis